Live Breaking News & Updates on P Muc1c Allo1

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an obser. ....

Naoki Okamura , Mark Gergen , Adam Pearson , Poseida Therapeutics Inc , Exchange Commission , Astellas Pharma Inc , Support Poseida , Redefining Cancer Cell , Poseida Board , Poseida Therapeutics , Focus Area Approach , Astella Primary Focuses , Chief Strategy Officer , Chief Executive , Site Specific Gene Editing , Looking Statements , Private Securities Litigation Reform Act , Press Release Image , Clinical Stage , P Muc1c Allo1 , Ar T , Press Release , Ews Release ,